Our innovative double-sided approach targeting both nNOS-stimulated melanoma progression and PD-L1-mediated tumor immunosuppression effectively enhanced the anti-melanoma activity of immunotherapy without producing more severe toxicity. Here, NOS1 is linked to neoplasm.